Anderson-Fabry disease in AustriaMorbus Fabry in Österreich

被引:0
|
作者
Matthias Lorenz
Anna-Christina Hauser
Margot Püspök-Schwarz
Peter Kotanko
Ingrid Arias
Herbert Zodl
Reinhard Kramar
Eduard Paschke
Till Voigtländer
Gere Sunder-Plassmann
机构
[1] University of Vienna,Division of Nephrology and Dialysis, Department of Medicine III
[2] University of Vienna,Department of Dermatology
[3] Lehrkrankenhaus der Karl-Franzens-Universität Graz,Department of Internal Medicine, Krankenhaus der Barmherzigen Brüder
[4] Krankenanstalt Rudolfstiftung,Third Department of Medicine
[5] Krankenhaus Wiener Neustadt,Second Department of Internal Medicine
[6] Krankenhaus der Kreuzschwestern,Third Department of Medicine
[7] University of Graz,Department of Pediatrics
[8] University of Vienna,Institute of Neurology
来源
关键词
Lysosomal storage diseases; Fabry disease; enzyme replacement therapy; end-stage renal disease; Lysosomale Speicherkrankheiten; Morbus Fabry; Enzymersatztherapie; terminale Niereninsuffizienz;
D O I
暂无
中图分类号
学科分类号
摘要
Fabry disease is an X-linked inherited inborn error of glycosphingolipid catabolism. The deficiency of α-galactosidase A leads to the deposition of glycosphingolipids primarily in lysosomes of blood vessel cells. In classically affected hemizygotes clinical manifestations include pain in the extremities, vessel ectasia (angiokeratoma) in skin and mucous membranes, ophtalmological abnormalities, and hypohidrosis. As disease progresses there is renal, cardiac, cerebral and vascular involvement, with most patients experiencing renal insufficiency, cardiac hypertrophy or stroke. Many female carriers of Fabry disease also have symptoms. Recently available enzyme replacement therapy has the potential to control or even reverse disease progression.
引用
收藏
页码:235 / 240
页数:5
相关论文
共 50 条
  • [21] Gastroenterological Complications of Anderson-Fabry Disease
    Buda, Piotr
    Ksiazyk, Janusz
    Tylki-Szymanska, Anna
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (33) : 6009 - 6013
  • [22] Renal involvement in Anderson-Fabry disease
    Sessa, A
    Meroni, M
    Battini, G
    Righetti, M
    Maglio, A
    Tosoni, A
    Nebuloni, M
    Vago, G
    Giordano, F
    JOURNAL OF NEPHROLOGY, 2003, 16 (02) : 310 - 313
  • [23] Hypertrophic cardiomyopathy in Anderson-Fabry disease
    Cecchi, Franco
    Frullini, Anna
    Olivotto, Iacopo
    Castelli, Gabriele
    Ciaccheri, Mauro
    Martinelli, Fabrizio
    Torricelli, Francesca
    Borsini, Walter
    Garbini, Francesca
    CLINICAL THERAPEUTICS, 2007, 29 : S93 - S94
  • [24] Misleading terms in Anderson-Fabry disease
    Weidemann, F.
    Strotmann, J. M.
    Breunig, F.
    Niemann, M.
    Maag, R.
    Baron, R.
    Eggert, A. O.
    Wanner, C.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2008, 38 (03) : 191 - 196
  • [25] The Cardiovascular Manifestations of Anderson-Fabry Disease
    Adeboye, Adedayo
    Alkhatib, Deya
    Latham, Samuel
    Jefferies, John
    CURRENT CARDIOVASCULAR RISK REPORTS, 2022, 16 (06) : 43 - 51
  • [26] Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy
    Morrissey, R. P.
    Philip, K. J.
    Schwarz, E. R.
    CARDIOVASCULAR JOURNAL OF AFRICA, 2011, 22 (01) : 38 - 44
  • [27] Kidney involvement in Anderson-Fabry disease
    Meroni, M
    Sessa, A
    Battini, G
    Tazzari, S
    Tarelli, LT
    HEREDITARY KIDNEY DISEASES, 1997, 122 : 178 - 184
  • [28] Enzyme replacement in Anderson-Fabry disease
    Bengtsson, BÅ
    Johansson, JO
    Hollak, C
    Linthorst, G
    FeldtRasmussen, U
    LANCET, 2003, 361 (9354): : 352 - 352
  • [29] GRANULOMATOUS GINGIVITIS IN ANDERSON-FABRY DISEASE
    YOUNG, WG
    PIHLSTROM, BL
    SAUK, JJ
    JOURNAL OF PERIODONTOLOGY, 1980, 51 (02) : 95 - 101
  • [30] The Cardiovascular Manifestations of Anderson-Fabry Disease
    Adedayo Adeboye
    Deya Alkhatib
    Samuel Latham
    John Jefferies
    Current Cardiovascular Risk Reports, 2022, 16 : 43 - 51